DiNuzzo Takes Over as CEO of Strategic Diagnostics, Terry to Advise GeneNews, Lapidus Joins T2 Board, and More | GenomeWeb
NEW YORK (GenomeWeb News) - Strategic Diagnostics has appointed Francis DiNuzzo to serve as president and CEO, and to sit on the company’s board of directors. He was named interim CEO earlier this year.
DiNuzzo formerly was executive VP and chief commercial officer, positions he took on in February 2008. He spent 26 years in the life and analytical sciences industries, and he has served as VP and GM of chemical solutions, consumables and services, and integrated biology solutions at Agilent Technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.